NO20071591L - Interleukin-9 og interleukin-4 kimaere antagonist muteiner og fremgangsmater for anvendelse derav. - Google Patents

Interleukin-9 og interleukin-4 kimaere antagonist muteiner og fremgangsmater for anvendelse derav.

Info

Publication number
NO20071591L
NO20071591L NO20071591A NO20071591A NO20071591L NO 20071591 L NO20071591 L NO 20071591L NO 20071591 A NO20071591 A NO 20071591A NO 20071591 A NO20071591 A NO 20071591A NO 20071591 L NO20071591 L NO 20071591L
Authority
NO
Norway
Prior art keywords
interleukin
methods
chimeric
mutein
antagonists
Prior art date
Application number
NO20071591A
Other languages
English (en)
Inventor
David C Boisvert
Malinda Longphre
Teresa M Wong
Sydney M Zaremba
Original Assignee
Aerovance Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aerovance Inc filed Critical Aerovance Inc
Publication of NO20071591L publication Critical patent/NO20071591L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • C12P21/02—Preparation of peptides or proteins having a known sequence of two or more amino acids, e.g. glutathione

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pulmonology (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Wood Science & Technology (AREA)
  • Transplantation (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

Kimæriske polypeptidantagonister som innbefatter et interleukin-4- (IL-4)-mutein bundet til et interleukin-9- (IL-9)-mutein er tilveiebrakt, og likeledes polynukleotider som koder for de kimæriske IL-4- og IL-9-muteinantagonister. Det er også tilveiebrakt metoder for anvendelse av de kimæriske muteinantagonister og kodende polypeptider til redusering eller hemming av en celles responsivitet overfor et cytokin så som IL-4, IL-9 og/eller interleukin-13. Metoder for anvendelse av preparatene til behandling av sykdommer så som lungesykdommer (feks. astma) er også tilveiebrakt.
NO20071591A 2004-09-22 2007-03-27 Interleukin-9 og interleukin-4 kimaere antagonist muteiner og fremgangsmater for anvendelse derav. NO20071591L (no)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US61227504P 2004-09-22 2004-09-22
US11/026,396 US7635754B2 (en) 2004-09-22 2004-12-29 Interleukin-9 and interleukin-4 chimeric antagonist muteins and methods of using same
PCT/US2005/034388 WO2006036878A2 (en) 2004-09-22 2005-09-21 Interleukin-9 and interleukin-4 chimeric antagonist muteins and methods of using same

Publications (1)

Publication Number Publication Date
NO20071591L true NO20071591L (no) 2007-06-21

Family

ID=36074534

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20071591A NO20071591L (no) 2004-09-22 2007-03-27 Interleukin-9 og interleukin-4 kimaere antagonist muteiner og fremgangsmater for anvendelse derav.

Country Status (12)

Country Link
US (2) US7635754B2 (no)
EP (1) EP1805198A4 (no)
JP (1) JP2008513518A (no)
KR (1) KR20070068396A (no)
AU (1) AU2005289639A1 (no)
BR (1) BRPI0516776A (no)
CA (1) CA2581469A1 (no)
IL (1) IL181898A (no)
NO (1) NO20071591L (no)
NZ (1) NZ553897A (no)
RU (1) RU2007114958A (no)
WO (1) WO2006036878A2 (no)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006121792A2 (en) 2005-05-05 2006-11-16 Archipelago Holdings, Inc. Unpriced order auction and routing
US7873561B1 (en) 2005-05-05 2011-01-18 Archipelago Holdings, Inc. Method and system for maintaining an order on a selected market center with maximum price exemption parameter
AU2006244562B2 (en) 2005-05-05 2012-05-17 Nyse Group, Inc. Reprice-to-block order
WO2006121796A2 (en) 2005-05-05 2006-11-16 Archipelago Holdings, Inc. Tracking liquidity order
US7912775B1 (en) 2005-05-05 2011-03-22 Archipelago Holdings, Inc. Liquidity analysis system and method
JP2009525267A (ja) * 2006-01-11 2009-07-09 アエロヴァンス インコーポレイティッド ヒトおよび非ヒト霊長類において喘息を処置するための方法および組成物
WO2009009775A1 (en) * 2007-07-11 2009-01-15 Aerovance, Inc. Pharmaceutical polypeptide dry powder aerosol formulation and method of preparation
US8771682B2 (en) 2011-04-26 2014-07-08 Technische Universtität Dresden Methods and compositions for reducing interleukin-4 or interleukin-13 signaling
EP3448413A1 (en) * 2016-04-26 2019-03-06 Five Prime Therapeutics, Inc. Treating respiratory diseases by targeting interleukin 4 induced 1 (il4i1)
KR20190133707A (ko) * 2017-03-31 2019-12-03 더 보드 어브 트러스티스 어브 더 리랜드 스탠포드 주니어 유니버시티 신테카인 조성물 및 사용방법
EP3530320B1 (en) * 2018-02-27 2023-11-15 Universitätsmedizin der Johannes Gutenberg-Universität Mainz Novel il-4-/il-13-derived peptide compounds for the treatment or prevention of neurodegenerative or neuroinflammatory diseases

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5011912A (en) * 1986-12-19 1991-04-30 Immunex Corporation Hybridoma and monoclonal antibody for use in an immunoaffinity purification system
US5399346A (en) * 1989-06-14 1995-03-21 The United States Of America As Represented By The Department Of Health And Human Services Gene therapy
US5225212A (en) * 1989-10-20 1993-07-06 Liposome Technology, Inc. Microreservoir liposome composition and method
US5314695A (en) * 1990-11-13 1994-05-24 Corvas International, Inc. Tissue factor based prothrombin time reagent
DE4137333A1 (de) * 1991-11-13 1993-05-19 W Prof Dr Sebald Therapeutische mittel, die antagonisten oder partielle agonisten des humanen interleukin 4 sind oder diese enthalten, hil-4-mutantenproteine sowie vefahren zu deren herstellung
US5395619A (en) * 1993-03-03 1995-03-07 Liposome Technology, Inc. Lipid-polymer conjugates and liposomes
DE4423131A1 (de) * 1994-07-01 1996-01-04 Bayer Ag Neue hIL-4-Mutantenproteine als Antagonisten oder partielle Agonisten des humanen Interleukin 4
CN1117155C (zh) * 1994-07-29 2003-08-06 史密丝克莱恩比彻姆有限公司 新型化合物
WO1997008321A1 (en) * 1995-08-24 1997-03-06 Magainin Pharmaceuticals Inc. Asthma associated factors as targets for treating atopic allergies including asthma and related disorders
EP0918858A1 (en) * 1996-05-10 1999-06-02 Biogen, Inc. Common gamma chain blocking agents
US5827533A (en) * 1997-02-06 1998-10-27 Duke University Liposomes containing active agents aggregated with lipid surfactants
WO2004021861A2 (en) 2002-09-03 2004-03-18 Vit Lauermann Targeted release
WO2004103295A2 (en) 2003-05-14 2004-12-02 Bayer Pharmaceuticals Corporation Interleukin-9 antagonist muteins and their pharmacological methods of use

Also Published As

Publication number Publication date
IL181898A0 (en) 2007-07-04
EP1805198A4 (en) 2010-01-20
EP1805198A2 (en) 2007-07-11
KR20070068396A (ko) 2007-06-29
AU2005289639A1 (en) 2006-04-06
JP2008513518A (ja) 2008-05-01
RU2007114958A (ru) 2008-10-27
CA2581469A1 (en) 2006-04-06
NZ553897A (en) 2011-01-28
US20060063236A1 (en) 2006-03-23
IL181898A (en) 2011-04-28
WO2006036878A3 (en) 2009-04-09
US20100099618A1 (en) 2010-04-22
US7635754B2 (en) 2009-12-22
BRPI0516776A (pt) 2008-09-23
WO2006036878A2 (en) 2006-04-06

Similar Documents

Publication Publication Date Title
NO20071591L (no) Interleukin-9 og interleukin-4 kimaere antagonist muteiner og fremgangsmater for anvendelse derav.
WO2002020767A3 (en) G-csf analog compositions and methods
ATE466085T1 (de) Protease-resistente modifizierte interferon alpha polypeptide
MA28843B1 (fr) Therapie d'association utilisant des proteines de fusion de trasferrine comprenant glp-1
NO20050749L (no) Nye alkyn-forbindelser med MCH-antagonistisk effekt og medikamenter inneholdende disse forbindelsene
WO2007110231A3 (en) MODIFIED INTERFERON-β (IFN-β) POLYPEPTIDES
ATE352300T1 (de) Zusammensetzung bestehend aus phentolaminmesylat und deren verwendung
HRP20050024A2 (en) Pegylated t20 polypeptide
DE60330923D1 (de) Menschliche Koagulationsfaktor VII Polypeptide
DK1687049T3 (da) Sprøjter, sprøjtegrænseflader og sprøjtestempler til anvendelse med medicinske injektorer
HK1077518A1 (en) Peptides that modulate nerve growth factor (ngf) activity, their compositions and use
EA201070129A1 (ru) Фармацевтический сухой порошкообразный аэрозольный состав, включающий полипептид, и способ его приготовления
BRPI0212919B8 (pt) "muteínas da lipocalina associada à gelatinase de neutrófilos humanos, proteínas relacionadas, composição farmacêutica, método para geração e uso das mesmas".
UY27760A1 (es) Nuevos derivados de pirrolidinio.
NO20063375L (no) Agonist-anti-trkC-antistoffer og fremgangsmater for a anvende disse
DE112005000942A5 (de) Modulare Vorrichtung zur Befeuchtung von Atemgas
CY1112655T1 (el) Γλυκοζυλιωμενη ιl-7, παρασκευη και χρησεις
DE602004030464D1 (de) Methode zur produktion und evaluierung der zytotoxizität von kir2dl nk-rezeptor antikörpern
AU2003257980A8 (en) Respiratory analyzer for exercise use
EA200401329A1 (ru) Способ лечения заболеваний, связанных с tweak
DE602005019416D1 (de) Zusammensetzung aus einem pulmonalen surfactant und einem von tnf stammenden peptid
NO20072005L (no) Nye heterocykliske amider
ATE477806T1 (de) Verwendung hyperbarischer bedingungen zur bereitstellung von neuroprotektion
DK471386A (da) Farmaceutisk komposition til behandling af leukopeni
WO2003087126A3 (en) Heteroclitic analogs and related methods

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application